Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has received a consensus rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $4.16.
Several research analysts have issued reports on SNSS shares. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research report on Thursday, August 24th. ValuEngine downgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald reissued a “hold” rating and set a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. Finally, UBS started coverage on shares of Sunesis Pharmaceuticals in a research report on Monday, November 20th. They set an “outperform” rating on the stock.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) traded down $0.08 during trading on Friday, reaching $3.28. 83,100 shares of the company’s stock traded hands, compared to its average volume of 133,059. Sunesis Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $4.45. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same period in the prior year, the firm earned ($0.62) EPS. research analysts forecast that Sunesis Pharmaceuticals will post -1.58 EPS for the current year.
In other news, Director Dayton Misfeldt bought 400,000 shares of the stock in a transaction dated Friday, October 27th. The shares were acquired at an average price of $2.00 per share, with a total value of $800,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Mpm Oncology Impact Management bought 25,300 shares of the stock in a transaction dated Thursday, November 2nd. The stock was purchased at an average cost of $2.59 per share, for a total transaction of $65,527.00. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 506,800 shares of company stock worth $1,091,282. Insiders own 10.21% of the company’s stock.
Several large investors have recently modified their holdings of SNSS. Renaissance Technologies LLC boosted its holdings in shares of Sunesis Pharmaceuticals by 1.1% in the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. boosted its holdings in shares of Sunesis Pharmaceuticals by 54.6% in the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 68,212 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Sunesis Pharmaceuticals by 77.4% in the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 18,254 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after acquiring an additional 23,819 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in shares of Sunesis Pharmaceuticals in the second quarter valued at about $208,000. 38.21% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/brokerages-set-sunesis-pharmaceuticals-inc-snss-price-target-at-4-16.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.